Drug Design, Development and Therapy (Nov 2019)
Delivery Of Curcumin Nanoliposomes Using Surface Modified With CD133 Aptamers For Prostate Cancer
Abstract
Qi Ma,1,* Wei Qian,2,* Wei Tao,2 Yanling Zhou,3 Boxin Xue2 1Department of Ultrasound, The Second Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China; 2Department of Urology, The Second Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China; 3Department of Operation, The Second Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China*These authors contributed equally to this workCorrespondence: Wei TaoDepartment of Urology, The Second Affiliated Hospital of Soochow University, No. 1055 Sanxiang Road, Gusu District, Suzhou City, Jiangsu Province, People’s Republic of ChinaTel/Fax +86 0512-67784837Email [email protected] ZhouDepartment of Operation, The Second Affiliated Hospital of Soochow University, No. 1055 Sanxiang Road, Gusu District, Suzhou City, Jiangsu Province, People’s Republic of ChinaEmail [email protected]: The aim of this study was to characterize curcumin (CUR)-loaded CD133 aptamer A15 liposomes for their antitumor activity in vitro and in vivo.Methods: The modified CUR liposomes were prepared by the thin-film hydration technique.Results: The particles showed spherical shape under electron microscopy with sizes Conclusion: These results indicate that A15 modified CUR liposomes are a promising candidate for antitumor drug delivery.Keywords: CD133 aptamers, curcumin, prostate cancer, liposomes, cell viability, cellular internalization, in vivo evaluation
